Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase IIb, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Neutralization of the Interferon Gene Signature and the Clinical Efficacy of IFNα-Kinoid in Adult Subjects With Systemic Lupus Erythematosus

Trial Profile

A Phase IIb, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Neutralization of the Interferon Gene Signature and the Clinical Efficacy of IFNα-Kinoid in Adult Subjects With Systemic Lupus Erythematosus

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 02 Oct 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Interferon alpha kinoid (Primary)
  • Indications Systemic lupus erythematosus
  • Focus Pharmacodynamics; Pharmacogenomic; Therapeutic Use
  • Sponsors Neovacs
  • Most Recent Events

    • 02 Oct 2019 According to a Neovacs media release, full results from the study were presented at the Key Opinion Leaders events hosted by the company.
    • 27 Mar 2019 According to a Neovacs media release, following the results of this study and as part of the latest transaction of the company with European Select Growth Opportunities Fund, the company expects to prepare for the next clinical stage and monitor the progress of patients treated as part of the five-year long-term follow-up program in accordance with the study protocol.
    • 20 Mar 2019 Planned End Date changed from 1 Dec 2018 to 1 Jun 2023.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top